< Back to Article

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony

Table 2

Baseline characteristics of lesions in subjects with leishmaniasis treated with imiquimod 5% cream plus pentavalent antimony versus placebo plus pentavalent antimony, participating in a randomized trial, Peru, 2006–7.

doi: https://doi.org/10.1371/journal.pntd.0000491.t002